dromlakhani Avoid testosterone therapy alone to prevent or treat diabetes in hypogonadism
STEP 1 — Gather Information
Confirm hypogonadism: presence of symptoms (e.g., low libido, ED, fatigue) and total testosterone <12 nmol/L on two morning fasting samples; assess diabetes status: HbA1c, fasting plasma glucose, oral glucose tolerance test if indicated; review current glucose‑lowering medications and lifestyle interventions.
STEP 2 — Rule In / Rule Out
Is the patient hypogonademic and being considered for testosterone therapy to prevent or treat diabetes? If yes, proceed to Step 3; if no, do not initiate testosterone for diabetes purposes.
STEP 3 — Classify or Stratify
Stratify glycemic status: normal glucose tolerance, prediabetes (HbA1c 5.7‑6.4%), or type 2 diabetes (HbA1c ≥6.5%); note any existing glucose‑lowering therapy.
STEP 4 — Decide
Do not use testosterone monotherapy for diabetes prevention or glycemic control; manage diabetes per standard guidelines (lifestyle, metformin, etc.) and consider testosterone only for hypogonadism symptoms per other ICSM recommendations.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on testosterone to replace glucose‑lowering agents; testosterone may modestly improve insulin resistance but is insufficient as sole therapy; monitor hematocrit, PSA, and symptoms; avoid in men seeking fertility; be aware that weight loss and exercise raise endogenous testosterone more effectively.
Concrete Clinical Example
A 58‑year‑old man with hypogonadism (total testosterone 9 nmol/L) and prediabetes (HbA1c 6.0%) asks whether a testosterone gel can prevent diabetes. The clinician advises lifestyle modification and metformin per ADA guidelines, not testosterone alone.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 20 on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036